chevron_leftBack
As of 24 April 2025, ALTEOGEN Inc. has a market cap of $14.52B USD, ranking #1248 globally and #16 in South Korea. It ranks #103 in the Healthcare sector, and #13 in the Biotechnology industry.
Key Stats
Market Cap
$14.52BUSD
20.73T KRW
Enterprise Value
$14.47BUSD
20.65T KRW
Revenue (TTM)
$72.05MUSD
102.85B KRW
EBITDA (TTM)
$19.79MUSD
28.25B KRW
Net Income (TTM)
$43.61MUSD
62.25B KRW
EBITDA Margin
27%
Profit Margin
61%
PE Ratio
333.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Soon-Jae Park
open_in_new
Employees
145
Founded
2008
Website
alteogen.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.1% | 6.4% | 5.4% | 14% | 1.7% | 135% |
Upcoming Earnings
Earnings Date
Thu, May 15
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
196170
(주)알테오젠
ISIN: KR7196170005
Shares Out.:
Shares Outstanding:
53.295M1
Shares Float:
38.842M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
389.0K KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About ALTEOGEN Inc.
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; and Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
